Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.19% | 18.24% | 41.72% | 20.38% | 3.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.30% | 44.65% | 42.65% | 2.72% | -10.29% |
| Operating Income | -69.30% | -44.65% | -42.65% | -2.72% | 10.29% |
| Income Before Tax | -83.25% | -54.73% | -46.68% | -6.23% | 9.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.25% | -54.73% | -46.68% | -6.23% | 9.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.25% | -54.73% | -46.68% | -6.23% | 9.31% |
| EBIT | -69.30% | -44.65% | -42.65% | -2.72% | 10.29% |
| EBITDA | -70.88% | -45.58% | -43.56% | -1.37% | 10.59% |
| EPS Basic | -79.09% | -37.35% | -7.94% | 22.30% | 33.91% |
| Normalized Basic EPS | -79.09% | -37.35% | -7.76% | 23.67% | 35.59% |
| EPS Diluted | -79.09% | -37.35% | -7.94% | 22.30% | 33.91% |
| Normalized Diluted EPS | -79.09% | -37.35% | -7.76% | 23.67% | 35.59% |
| Average Basic Shares Outstanding | 2.32% | 12.65% | 35.89% | 36.72% | 37.22% |
| Average Diluted Shares Outstanding | 2.32% | 12.65% | 35.89% | 36.72% | 37.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |